FDA launches new priority review voucher program for select biopharmas

Reblozyl (luspatercept–aamt)

Bristol Myers Squibb CEO Giovanni Caforio debuts new brand
Biotech

Bristol Myers says Celgene buyout could boost sales to $20B

Thanks to Celgene, Bristol Myers' thinks its late-stage pipeline will rake in $20 billion in yearly sales starting in 2025, up from $15 billion.
Amirah Al Idrus Jun 25, 2020 11:45am
Lungs illustration Image Pixabay

Acceleron's PAH drug sotatercept hits the mark in phase 2

Jan 27, 2020 5:42pm